PDF(Pubmed)
Abstract：
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is classified under fibrotic interstitial pneumonia, characterized by a chronic and progressive course. The predominant clinical features of IPF include dyspnea and pulmonary dysfunction.
OBJECTIVE: To assess the effects of pirfenidone in the early treatment of IPF on lung function in patients.
METHODS: A retrospective analysis was performed on 113 patients with IPF who were treated in our hospital from November 2017 to January 2023. These patients were divided into two groups: control group (n = 53) and observation group (n = 60). In the control group, patients received routine therapy in combination with methylprednisolone tablets, while those in the observation group received routine therapy together with pirfenidone. After applying these distinct treatment approaches to the two groups, we assessed several parameters, including the overall effectiveness of clinical therapy, the occurrence of adverse reactions (e.g., nausea, vomiting, and anorexia), symptom severity scores, pulmonary function index levels, inflammatory marker levels, and the 6-min walk distance before and after treatment in both groups.
RESULTS: The observation group exhibited significantly higher rates than the control group after therapy, with a clear distinction (P < 0.05). After treatment, the observation group experienced significantly fewer adverse reactions than the control group, with a noticeable difference (P < 0.05). When analyzing the symptom severity scores between the two groups of patients after treatment, the observation group had significantly lower scores than the control group, with a distinct difference (P < 0.05). When comparing the pulmonary function index levels between the two groups of patients after therapy, the observation group displayed significantly higher levels than the control group, with a noticeable difference (P < 0.05). Evaluating the inflammatory marker data (C-reactive protein, interleukin-2 [IL-2], and IL-8) between the two groups of patients after therapy, the observation group exhibited significantly lower levels than the control group, with significant disparities (P < 0.05). Comparison of the 6-min walking distance data between the two groups of patients after treatment showed that the observation group achieved significantly greater distances than the control group, with a marked difference (P < 0.05).
CONCLUSIONS: Prompt initiation of pirfenidone treatment in individuals diagnosed with IPF can enhance pulmonary function, elevate inflammatory factor levels, and increase the distance covered in the 6-min walk test. This intervention is conducive to effectively decreasing the occurrence of adverse reactions in patients.
OBJECTIVE: To assess the effects of pirfenidone in the early treatment of IPF on lung function in patients.
METHODS: A retrospective analysis was performed on 113 patients with IPF who were treated in our hospital from November 2017 to January 2023. These patients were divided into two groups: control group (n = 53) and observation group (n = 60). In the control group, patients received routine therapy in combination with methylprednisolone tablets, while those in the observation group received routine therapy together with pirfenidone. After applying these distinct treatment approaches to the two groups, we assessed several parameters, including the overall effectiveness of clinical therapy, the occurrence of adverse reactions (e.g., nausea, vomiting, and anorexia), symptom severity scores, pulmonary function index levels, inflammatory marker levels, and the 6-min walk distance before and after treatment in both groups.
RESULTS: The observation group exhibited significantly higher rates than the control group after therapy, with a clear distinction (P < 0.05). After treatment, the observation group experienced significantly fewer adverse reactions than the control group, with a noticeable difference (P < 0.05). When analyzing the symptom severity scores between the two groups of patients after treatment, the observation group had significantly lower scores than the control group, with a distinct difference (P < 0.05). When comparing the pulmonary function index levels between the two groups of patients after therapy, the observation group displayed significantly higher levels than the control group, with a noticeable difference (P < 0.05). Evaluating the inflammatory marker data (C-reactive protein, interleukin-2 [IL-2], and IL-8) between the two groups of patients after therapy, the observation group exhibited significantly lower levels than the control group, with significant disparities (P < 0.05). Comparison of the 6-min walking distance data between the two groups of patients after treatment showed that the observation group achieved significantly greater distances than the control group, with a marked difference (P < 0.05).
CONCLUSIONS: Prompt initiation of pirfenidone treatment in individuals diagnosed with IPF can enhance pulmonary function, elevate inflammatory factor levels, and increase the distance covered in the 6-min walk test. This intervention is conducive to effectively decreasing the occurrence of adverse reactions in patients.
摘要：
背景：特发性肺纤维化（IPF）被归类为纤维化间质性肺炎，以慢性和进行性过程为特征。IPF的主要临床特征包括呼吸困难和肺功能障碍。
目的：评价吡非尼酮早期治疗IPF对患者肺功能的影响。
方法：回顾性分析2017年11月至2023年1月在我院接受治疗的113例IPF患者。将这些患者分为两组：对照组（n=53）和观察组（n=60）。在对照组中，患者接受常规治疗联合甲基强的松龙片，观察组在常规治疗的同时给予吡非尼酮。在将这些不同的治疗方法应用于两组后，我们评估了几个参数，包括临床治疗的总体有效性，不良反应的发生(例如，恶心,呕吐,和厌食症)，症状严重程度评分，肺功能指标水平，炎症标志物水平，两组治疗前后6min步行距离。
结果：治疗后观察组的发生率明显高于对照组，有明显区别(P<0.05)。治疗后,观察组不良反应明显少于对照组,差异有统计学意义(P<0.05)。分析两组患者治疗后的症状严重程度评分,观察组评分明显低于对照组,差异有统计学意义(P<0.05)。比较两组患者治疗后肺功能指标水平,观察组明显高于对照组,差异有统计学意义(P<0.05)。评估炎症标志物数据(C反应蛋白，白细胞介素-2[IL-2]，和IL-8）在治疗后两组患者之间，观察组明显低于对照组,差异显著(P<0.05)。两组患者治疗后6min步行距离数据比较显示,观察组达到的距离明显大于对照组,差异有统计学意义(P<0.05)。
结论：在诊断为IPF的个体中迅速开始吡非尼酮治疗可以增强肺功能，升高炎症因子水平，并增加6分钟步行测试中覆盖的距离。该干预措施有利于有效减少患者不良反应的发生。
目的：评价吡非尼酮早期治疗IPF对患者肺功能的影响。
方法：回顾性分析2017年11月至2023年1月在我院接受治疗的113例IPF患者。将这些患者分为两组：对照组（n=53）和观察组（n=60）。在对照组中，患者接受常规治疗联合甲基强的松龙片，观察组在常规治疗的同时给予吡非尼酮。在将这些不同的治疗方法应用于两组后，我们评估了几个参数，包括临床治疗的总体有效性，不良反应的发生(例如，恶心,呕吐,和厌食症)，症状严重程度评分，肺功能指标水平，炎症标志物水平，两组治疗前后6min步行距离。
结果：治疗后观察组的发生率明显高于对照组，有明显区别(P<0.05)。治疗后,观察组不良反应明显少于对照组,差异有统计学意义(P<0.05)。分析两组患者治疗后的症状严重程度评分,观察组评分明显低于对照组,差异有统计学意义(P<0.05)。比较两组患者治疗后肺功能指标水平,观察组明显高于对照组,差异有统计学意义(P<0.05)。评估炎症标志物数据(C反应蛋白，白细胞介素-2[IL-2]，和IL-8）在治疗后两组患者之间，观察组明显低于对照组,差异显著(P<0.05)。两组患者治疗后6min步行距离数据比较显示,观察组达到的距离明显大于对照组,差异有统计学意义(P<0.05)。
结论：在诊断为IPF的个体中迅速开始吡非尼酮治疗可以增强肺功能，升高炎症因子水平，并增加6分钟步行测试中覆盖的距离。该干预措施有利于有效减少患者不良反应的发生。
